amantadine has been researched along with Abnormal Movements in 20 studies
amant: an antiviral compound consisting of an adamantane derivative chemically linked to a water-solube polyanioic matrix; structure in first source
| Excerpt | Relevance | Reference |
|---|---|---|
| " The most frequent adverse events (AEs) were dry mouth, constipation, and insomnia." | 6.90 | Safety and efficacy of ADS-5102 (amantadine) extended release capsules to improve walking in multiple sclerosis: A randomized, placebo-controlled, phase 2 trial. ( Brown, TR; Chernoff, DN; Cohen, JA; Gudesblatt, M; Hunter, SF; Llorens, L; Patni, R; Ruby, AE; Souza-Prien, CJ; Thrower, BW, 2019) |
| "Amantadine is an antiviral drug available in oral and intravenous forms." | 2.90 | Effect of Repeated Intravenous Amantadine Infusions in Patients with Parkinson's Disease: An Open-Label Pilot Study. ( Djaldetti, R; Khlebtovsky, A; Steiner, I; Treves, T, 2019) |
| " The most frequent adverse events (AEs) were dry mouth, constipation, and insomnia." | 2.90 | Safety and efficacy of ADS-5102 (amantadine) extended release capsules to improve walking in multiple sclerosis: A randomized, placebo-controlled, phase 2 trial. ( Brown, TR; Chernoff, DN; Cohen, JA; Gudesblatt, M; Hunter, SF; Llorens, L; Patni, R; Ruby, AE; Souza-Prien, CJ; Thrower, BW, 2019) |
| " ADS-5102 is an extended release amantadine capsule formulation, designed for once-daily dosing at bedtime (qhs) to provide high concentrations upon waking and throughout the day, with lower concentrations in the evening." | 2.90 | Pharmacokinetics of ADS-5102 (Amantadine) Extended Release Capsules Administered Once Daily at Bedtime for the Treatment of Dyskinesia. ( Hauser, RA; Johnson, R; McClure, N; Nguyen, JT; Pahwa, R; Patni, R; Souza-Prien, CJ; Wargin, WA; Went, GT, 2019) |
| "In Parkinson's disease, dyskinesias result from disease progression and chronic levodopa therapy." | 2.90 | Impact of dyskinesia on activities of daily living in Parkinson's disease: Results from pooled phase 3 ADS-5102 clinical trials. ( Deik, A; Isaacson, S; Jimenez-Shaheed, J; Johnson, R; Malaty, IA; Pahwa, R; Patni, R, 2019) |
| "Dyskinesias are some of the major motor complications that impair quality of life for patients with Parkinson's disease." | 2.75 | Amantadine for dyskinesias in Parkinson's disease: a randomized controlled trial. ( Hisanaga, K; Kawamura, T; Kuno, S; Nomoto, M; Oeda, T; Sawada, H; Yamamoto, K; Yamamoto, M, 2010) |
| "300 mg amantadine reduces dyskinesia in Parkinson's disease by approximately 45% but the benefit lasted less than eight months." | 2.71 | Duration of amantadine benefit on dyskinesia of severe Parkinson's disease. ( Armellino, K; Di Iorio, A; Iacono, D; Luciano, AL; Onofrj, M; Thomas, A, 2004) |
| "Abnormal involuntary movements known as dyskinesias are amongst the most disabling side-effects of levodopa therapy." | 2.42 | Amantadine for dyskinesia in Parkinson's disease. ( Clarke, CE; Crosby, NJ; Deane, KH, 2003) |
| "LTG, amantadine, and VPA were withdrawn, the remaining 2 drugs, benzhexol and compound preparation (flupentixol and melitracen), were continued to use, and the patient improved in 2." | 1.46 | Disabling tremor induced by long-term use of sodium valproate and lamotrigine: Case report. ( Chen, J; He, ZF; Rao, Z; Wang, XH; Zhou, CN, 2017) |
| "The development of dyskinesias following chronic L-DOPA replacement therapy remains a major problem in the long-term treatment of Parkinson's disease." | 1.39 | IRC-082451, a novel multitargeting molecule, reduces L-DOPA-induced dyskinesias in MPTP Parkinsonian primates. ( Aron Badin, R; Auguet, M; Bertrand, A; Boulet, S; Brouillet, E; Chabrier, PE; Dollé, F; Gaillard, MC; Guillermier, M; Hantraye, P; Jan, C; Malgorn, C; Savasta, M; Spinnewyn, B; Van Camp, N, 2013) |
| "Pergolide was increased to 8." | 1.33 | High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesias. ( Hundemer, HP; Oehlwein, C; Polzer, U; Schwarz, J; Storch, A; Trenkwalder, C; Winkelmann, J, 2005) |
| "Amantadine was therefore discontinued." | 1.33 | Dyskinesias induced by subthalamotomy in Parkinson's disease are unresponsive to amantadine. ( Antico, J; Merello, M; Obeso, JA; Perez-Lloret, S, 2006) |
| "Motor complications and disease progression are responsible for devastating morbidity." | 1.32 | A young onset Parkinson's patient: a case study. ( Jung, SK, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (35.00) | 29.6817 |
| 2010's | 13 (65.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Khlebtovsky, A | 1 |
| Steiner, I | 1 |
| Treves, T | 1 |
| Djaldetti, R | 1 |
| Wagle Shukla, A | 2 |
| Pahwa, R | 3 |
| Hauser, RA | 2 |
| Cohen, JA | 1 |
| Hunter, SF | 1 |
| Brown, TR | 1 |
| Gudesblatt, M | 1 |
| Thrower, BW | 1 |
| Llorens, L | 1 |
| Souza-Prien, CJ | 2 |
| Ruby, AE | 1 |
| Chernoff, DN | 1 |
| Patni, R | 3 |
| He, ZF | 1 |
| Chen, J | 1 |
| Zhou, CN | 1 |
| Rao, Z | 1 |
| Wang, XH | 1 |
| Wargin, WA | 1 |
| McClure, N | 1 |
| Johnson, R | 2 |
| Nguyen, JT | 1 |
| Went, GT | 1 |
| Zubair, UB | 1 |
| Majid, H | 1 |
| Isaacson, S | 1 |
| Jimenez-Shaheed, J | 1 |
| Malaty, IA | 1 |
| Deik, A | 1 |
| Tronci, E | 1 |
| Fidalgo, C | 1 |
| Zianni, E | 1 |
| Collu, M | 1 |
| Stancampiano, R | 1 |
| Morelli, M | 1 |
| Gardoni, F | 1 |
| Carta, M | 1 |
| Ikeda, K | 1 |
| Yoshikawa, S | 1 |
| Kurokawa, T | 1 |
| Yuzawa, N | 1 |
| Nakao, K | 1 |
| Mochizuki, H | 1 |
| Sawada, H | 1 |
| Oeda, T | 1 |
| Kuno, S | 1 |
| Nomoto, M | 1 |
| Yamamoto, K | 1 |
| Yamamoto, M | 1 |
| Hisanaga, K | 1 |
| Kawamura, T | 1 |
| Paquette, MA | 1 |
| Martinez, AA | 1 |
| Macheda, T | 1 |
| Meshul, CK | 1 |
| Johnson, SW | 1 |
| Berger, SP | 1 |
| Giuffrida, A | 1 |
| Aron Badin, R | 1 |
| Spinnewyn, B | 1 |
| Gaillard, MC | 1 |
| Jan, C | 1 |
| Malgorn, C | 1 |
| Van Camp, N | 1 |
| Dollé, F | 1 |
| Guillermier, M | 1 |
| Boulet, S | 1 |
| Bertrand, A | 1 |
| Savasta, M | 1 |
| Auguet, M | 1 |
| Brouillet, E | 1 |
| Chabrier, PE | 1 |
| Hantraye, P | 1 |
| Crosby, NJ | 1 |
| Deane, KH | 1 |
| Clarke, CE | 1 |
| Thomas, A | 1 |
| Iacono, D | 1 |
| Luciano, AL | 1 |
| Armellino, K | 1 |
| Di Iorio, A | 1 |
| Onofrj, M | 1 |
| Hill, MP | 1 |
| Ravenscroft, P | 1 |
| Bezard, E | 1 |
| Crossman, AR | 1 |
| Brotchie, JM | 1 |
| Michel, A | 1 |
| Grimée, R | 1 |
| Klitgaard, H | 1 |
| Jung, SK | 1 |
| Storch, A | 1 |
| Trenkwalder, C | 1 |
| Oehlwein, C | 1 |
| Winkelmann, J | 1 |
| Polzer, U | 1 |
| Hundemer, HP | 1 |
| Schwarz, J | 1 |
| Merello, M | 1 |
| Perez-Lloret, S | 1 |
| Antico, J | 1 |
| Obeso, JA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)[NCT02202551] | Phase 3 | 223 participants (Actual) | Interventional | 2014-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"To evaluate clinical progression of PD as assessed by the MDS-UPDRS, combined score, Parts I, II, and III.~Part I - non-motor experiences of daily living; Part II - motor experiences of daily living; Part III - motor examination. Parts I and II each contain 13 questions measured on a 5-point scale (0-4). Part III contains 18 objective rater assessments of the motor signs of PD measured on a 5-point scale (0-4).~Total range for combined score (Part I-III) is = 0-176. Generally for MDS-UPDRS scores and sub-scores, the lower the score, the better.~Parts I, II, and III are summed to make the total score." (NCT02202551)
Timeframe: Up to 101 weeks. MDS-UPDRS was performed at the following visits: Screening, Week 8, Week 16, Week 28, Week 40, Week 52, Week 64, Week 76, Week 88, Week 100 (or ET).
| Intervention | units on a scale (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Change from Baseline at Week 8 | Change from Baseline at Week 16 | Change from Baseline at Week 28 | Change from Baseline at Week 40 | Change from Baseline at Week 52 | Change from Baseline at Week 64 | Change from Baseline at Week 76 | Change from Baseline at Week 88 | Change from Baseline at Week 100 | |
| ADS-5102 1A | 41.8 | 1.2 | 1.6 | 4.8 | 7.5 | 13.2 | 8.8 | 11.7 | 11.3 | 11.4 |
| ADS-5102 Group 1P | 45.6 | -2.8 | -1.4 | 1.5 | -0.4 | 2.6 | 2.6 | 7.3 | 3.7 | 3.7 |
| ADS-5102 Group 2 | 52.8 | 0.8 | 5.7 | 6.5 | 1.6 | 6.1 | 6.1 | 9.4 | 6.4 | 6.5 |
| ADS-5102 Group 3 | 52.4 | -5.3 | -5.2 | -5.3 | -4.8 | -4.6 | -4.6 | -4.9 | 0.9 | 4.1 |
"This component (Questions 4.1 - 4.6) includes time spent with dyskinesia, functional impact of dyskinesia, time spent in OFF state, functional impact of fluctuations, complexity of motor fluctuations, painful OFF-state dystonia. Questions 4.1-4.6 are summed to make the Part IV score.~Generally for MDS-UPDRS scores and sub-scores, the lower the score, the better. Total range for Part IV is = 0-24" (NCT02202551)
Timeframe: 100 Weeks. MDS-UPDRS was performed at the following visits: Screening, Week 8, Week 16, Week 28, Week 40, Week 52, Week 64, Week 76, Week 88, Week 100 (or ET).
| Intervention | units on a scale (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Change in Baseline from Week 8 | Change in Baseline from Week 16 | Change from Baseline at Week 28 | Change from Baseline at Week 40 | Change from Baseline at Week 52 | Change from Baseline at Week 64 | Change from Baseline at Week 76 | Change from Baseline at Week 88 | Change from Baseline at Week 100 | |
| Group 1a | 6.5 | -0.2 | -0.8 | -0.3 | 0.0 | 0.2 | 0.4 | 0.9 | 0.4 | 0.4 |
| Group 1P | 9.6 | -3.4 | -3.2 | -3.3 | -2.8 | -2.9 | -3.3 | -2.9 | -2.8 | -2.4 |
| Group 2 | 9.8 | -3.6 | -1.1 | -1.4 | -2.9 | -2.5 | -1.9 | -2.7 | -3.7 | -3.6 |
| Group 3 | 10.4 | -4.0 | -3.9 | -4.4 | -4.7 | -3.6 | -2.5 | -3.7 | -4.3 | -3.6 |
The primary objective of the study was to evaluate the safety and tolerability of ADS-5102 oral capsules, an extended release (ER) formulation of amantadine, administered at a dose of 340 mg once daily at bedtime for the treatment of levodopa-induced dyskinesia (LID) in subjects with Parkinson's disease (PD). (NCT02202551)
Timeframe: Up to 101 weeks
| Intervention | Participants (Count of Participants) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| AE | Study drug-related AE | SAEs | Permanent discontinuation due to AE | Permanent discontinuation due to drug-related AE | Mild AEs | Moderate AEs | Mild drug-related AE | Moderate drug-related AE | Severe drug-related AE | |
| Group 1a | 57 | 31 | 16 | 12 | 4 | 12 | 25 | 16 | 12 | 3 |
| Group 1P | 70 | 45 | 21 | 21 | 15 | 13 | 36 | 15 | 23 | 7 |
| Group 2 | 23 | 16 | 6 | 6 | 4 | 3 | 13 | 3 | 12 | 1 |
| Group 3 | 55 | 32 | 17 | 10 | 8 | 11 | 26 | 5 | 22 | 5 |
1 review available for amantadine and Abnormal Movements
| Article | Year |
|---|---|
Amantadine for dyskinesia in Parkinson's disease.
Topics: Amantadine; Antiparkinson Agents; Dyskinesias; Humans; Parkinson Disease; Randomized Controlled Tria | 2003 |
6 trials available for amantadine and Abnormal Movements
| Article | Year |
|---|---|
Effect of Repeated Intravenous Amantadine Infusions in Patients with Parkinson's Disease: An Open-Label Pilot Study.
Topics: Aged; Amantadine; Antiparkinson Agents; Drug Administration Schedule; Dyskinesias; Female; Humans; I | 2019 |
Safety and efficacy of ADS-5102 (amantadine) extended release capsules to improve walking in multiple sclerosis: A randomized, placebo-controlled, phase 2 trial.
Topics: Adult; Aged; Amantadine; Delayed-Action Preparations; Dopamine Agents; Double-Blind Method; Dyskines | 2019 |
Pharmacokinetics of ADS-5102 (Amantadine) Extended Release Capsules Administered Once Daily at Bedtime for the Treatment of Dyskinesia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Cross-Over Studies; De | 2019 |
Impact of dyskinesia on activities of daily living in Parkinson's disease: Results from pooled phase 3 ADS-5102 clinical trials.
Topics: Activities of Daily Living; Aged; Amantadine; Antiparkinson Agents; Delayed-Action Preparations; Dys | 2019 |
Amantadine for dyskinesias in Parkinson's disease: a randomized controlled trial.
Topics: Adult; Aged; Amantadine; Antiparkinson Agents; Cross-Over Studies; Double-Blind Method; Dyskinesias; | 2010 |
Duration of amantadine benefit on dyskinesia of severe Parkinson's disease.
Topics: Aged; Amantadine; Dopamine Agents; Double-Blind Method; Dyskinesias; Female; Humans; Levodopa; Male; | 2004 |
13 other studies available for amantadine and Abnormal Movements
| Article | Year |
|---|---|
Extended-Release Amantadine-A Smart Pill for Treatment of Levodopa-Induced Dyskinesia but Does the Evidence Justify the Cost?
Topics: Amantadine; Antiparkinson Agents; Delayed-Action Preparations; Dyskinesias; Humans; Levodopa; Parkin | 2017 |
ADS 5102 (Amantadine) Extended Release for Levodopa-Induced Dyskinesia-Reply.
Topics: Amantadine; Antiparkinson Agents; Dyskinesias; Humans; Levodopa | 2017 |
ADS-5102 (Amantadine) Extended Release for Levodopa-Induced Dyskinesia.
Topics: Amantadine; Antiparkinson Agents; Dyskinesias; Humans; Levodopa | 2017 |
Disabling tremor induced by long-term use of sodium valproate and lamotrigine: Case report.
Topics: Amantadine; Anticonvulsants; Antiparkinson Agents; Dyskinesia, Drug-Induced; Dyskinesias; Humans; La | 2017 |
Anti-NMDA Receptor Encephalitis in a Young Girl with Altered Behaviour and Abnormal Movements.
Topics: Adolescent; Amantadine; Anti-N-Methyl-D-Aspartate Receptor Encephalitis; Autoantibodies; Bromocripti | 2018 |
Effect of memantine on L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease.
Topics: Amantadine; Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesias; Excitatory Amino Aci | 2014 |
TRK-820, a selective kappa opioid receptor agonist, could effectively ameliorate L-DOPA-induced dyskinesia symptoms in a rat model of Parkinson's disease.
Topics: Amantadine; Animals; Behavior, Animal; Disease Models, Animal; Dyskinesias; Extracellular Space; Lev | 2009 |
Anti-dyskinetic mechanisms of amantadine and dextromethorphan in the 6-OHDA rat model of Parkinson's disease: role of NMDA vs. 5-HT1A receptors.
Topics: Amantadine; Animals; Antiparkinson Agents; Cycloserine; Dextromethorphan; Dopamine Agents; Dyskinesi | 2012 |
IRC-082451, a novel multitargeting molecule, reduces L-DOPA-induced dyskinesias in MPTP Parkinsonian primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antioxidants; Antiparkinson Agent | 2013 |
Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease.
Topics: Amantadine; Animals; Anticonvulsants; Antiparkinson Agents; Callithrix; Disease Models, Animal; Drug | 2004 |
A young onset Parkinson's patient: a case study.
Topics: Activities of Daily Living; Adult; Age of Onset; Amantadine; Antiparkinson Agents; Carbidopa; Combin | 2004 |
High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesias.
Topics: Adult; Aged; Amantadine; Antiparkinson Agents; Antipsychotic Agents; Clozapine; Drug Therapy, Combin | 2005 |
Dyskinesias induced by subthalamotomy in Parkinson's disease are unresponsive to amantadine.
Topics: Adult; Aged; Amantadine; Antiparkinson Agents; Dominance, Cerebral; Dyskinesias; Electric Stimulatio | 2006 |